BioStock: PHI’s CEO comments on the approved US listing

August 21, 2024
Language flag

Phase Holographic Imaging has been approved for a dual US listing in addition to its primary listing on the Swedish Spotlight market. What does this mean for the company’s shareholders, and how might it impact the company’s long-term valuation? BioStock reached out to PHI’s CEO Patrik Eschricht to discuss this and the upcoming redemption of the TO4 warrants that could potentially raise SEK 20.8 million in October.

Read the full interview with Patrik Eschricht on biostock.se.

The dual listing on the OTCQB market represents a significant step in
making PHI’s shares more accessible to US investors. This listing
increases our visibility in the US, aligning with our strategic focus on
expanding into the regenerative medicine market.

Further reading

Schematic, blue image of an egg cell held by a pipette.

Biostock: PHI comments on expansion into veterinary IVF

Phase Holographic Imaging is broadening its focus. The company, which previously operated in regenerative medicine and cell therapy, is now adding the fast-growing field of in vitro fertilization, IVF, for livestock to its pipeline. BioStock contacted CEO Patrik Eschricht to learn more about the decision and what opportunities he sees with the new venture.
A hand holding a microphone against a dark background.

Biostock inverview with acting CEO: ”We aim to drive innovation that accelerates breakthroughs in regenerative medicine”

With the introduction of the HoloMonitor CellSync, Phase Holographic Imaging (PHI) leaps forward in live cell imaging technology. Currently in the final stages of development, this next-generation imaging system is undergoing pre-production testing at prestigious U.S. institutions – the Huntsman Cancer Institute and the Wake Forest Institute of Regenerative Medicine. Biostock has interviewed the acting CEO, Ivan Jurković, to learn more.
A journal cover from Advanced Biology with yellow and blue melanocytes and melanoma cells.

Picture-Perfect Science! HoloMonitor® Images Featured on Cover of Advanced Biology

We are proud to announce that a recent study utilizing HoloMonitor® M4 has been featured on the cover of Advanced Biology, Volume 9, Issue 2 (February 2025). The study, led by Dr. Besa Xhabija and colleagues at the University of Michigan-Dearborn, USA, demonstrates the transformative potential of HoloMonitor, our non-invasive, real-time live cell imaging system, in advancing melanoma research.
PHI-global-biostock

BioStock: Kapitalanskaffning ska driva PHI:s globala expansion

PHI genomför just nu en företrädesemission om cirka 64 Mkr. Målet är att öka den globala försäljningen på marknaden för holografisk mikroskopi och icke-invasiv cellanalys. Bolaget, under ledning av nye vd Anders Månsson, fokuserar nu på att öka tillväxttakten väsentligt, vilket underlättas av att man har en färdig produkt inom ett segment som spås växa starkt under kommande år, samt av den större marknadsnärvaro man har möjlighet till genom samarbetet med Altium.
123…10

Latest News

Schematic, blue image of an egg cell held by a pipette.

Biostock: PHI comments on expansion into veterinary IVF

Phase Holographic Imaging is broadening its focus. The company, which previously operated in regenerative medicine and cell therapy, is now adding the fast-growing field of in vitro fertilization, IVF, for livestock to its pipeline. BioStock contacted CEO Patrik Eschricht to learn more about the decision and what opportunities he sees with the new venture.
A brown cow with a calf on a green field-

PHI sets sights on IVF applications in livestock

Phase Holographic Imaging PHI AB (“PHI” or the “Company”), a leading provider of advanced holographic imaging solutions, announces its strategic expansion into in vitro fertilization (IVF) in livestock – a growing field where advanced imaging can improve the assessment of oocytes and embryos in livestock breeding. The initiative leverages PHI’s core Quantitative Phase Imaging (QPI) technology and will explore how label-free, non-invasive imaging can make IVF in cows and horses more consistent, efficient, and scalable. PHI’s next-generation HoloMonitor®, which the new IVF-initiative is based on, is set to be launched later this year and PHI has officially filed a trademark application for HoloOocyte.
wetransfer_4

Interim Report 1 2025/26

The first quarter of the fiscal year marks a pivotal moment for PHI as we continue to build momentum across our strategic pillars. Our commitment to innovation, clinical integration, and global expansion remains steadfast, and the progress made this quarter reflects the dedication and ingenuity of our entire team.
See All News